News | August 05, 2024
Roche closes acquisition of LumiraDx’s Point of Care technology
The acquisition of LumiraDx’s Point of Care technology received all required antitrust and regulatory clearances
The acquisition of LumiraDx’s Point of Care technology received all required antitrust and regulatory clearances
The built-in AI-trained algorithms will empower users to proactively intervene when their glucose levels require attention and before a complication can even occur
Roche will pay a purchase price of USD 295 million and an additional payment of up to USD 55 million
Almost 300 million people globally have chronic hepatitis B
Subscribe To Our Newsletter & Stay Updated
